These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

62 related items for PubMed ID: 2567742

  • 1. A preliminary dose-ranging trial of proglumide for the treatment of refractory schizophrenics.
    Hicks PB, Vinogradov S, Riney SJ, Su K, Csernansky JG.
    J Clin Psychopharmacol; 1989 Jun; 9(3):209-12. PubMed ID: 2567742
    [Abstract] [Full Text] [Related]

  • 2. Placebo-controlled, double-blind study of the effects of proglumide in the treatment of schizophrenia.
    Whiteford HA, Stedman TJ, Welham J, Csernansky JG, Pond SM.
    J Clin Psychopharmacol; 1992 Oct; 12(5):337-40. PubMed ID: 1362205
    [Abstract] [Full Text] [Related]

  • 3. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia.
    Meltzer HY, Sommers AA, Luchins DJ.
    J Clin Psychopharmacol; 1986 Dec; 6(6):329-38. PubMed ID: 2879856
    [Abstract] [Full Text] [Related]

  • 4. [Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial].
    Shiloh R, Weizman A, Weizer N, Dorfman-Etrog P, Munitz H.
    Harefuah; 2001 May; 140(5):369-73, 456. PubMed ID: 11419053
    [Abstract] [Full Text] [Related]

  • 5. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.
    Faraone SV, Brown WA, Laughren TP.
    J Clin Psychiatry; 1987 Apr; 48(4):151-4. PubMed ID: 2881923
    [Abstract] [Full Text] [Related]

  • 6. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial.
    Leiderman E, Zylberman I, Zukin SR, Cooper TB, Javitt DC.
    Biol Psychiatry; 1996 Feb 01; 39(3):213-5. PubMed ID: 8837983
    [No Abstract] [Full Text] [Related]

  • 7. A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse.
    Steingard S, Allen M, Schooler NR.
    J Clin Psychiatry; 1994 Nov 01; 55(11):470-2. PubMed ID: 7989278
    [Abstract] [Full Text] [Related]

  • 8. Low-dose loxapine in the treatment of schizophrenia: is it more effective and more "atypical" than standard-dose loxapine?
    Meltzer HY, Jayathilake K.
    J Clin Psychiatry; 1999 Nov 01; 60 Suppl 10():47-51. PubMed ID: 10340687
    [Abstract] [Full Text] [Related]

  • 9. Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data.
    Deutsch SI, Rosse RB, Kendrick KA, Fay-McCarthy M, Collins JP, Wyatt RJ.
    Clin Neuropharmacol; 1993 Dec 01; 16(6):518-24. PubMed ID: 9377587
    [Abstract] [Full Text] [Related]

  • 10. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
    Szymanski S, Lieberman J, Pollack S, Kane JM, Safferman A, Munne R, Umbricht D, Woerner M, Masiar S, Kronig M.
    Biol Psychiatry; 1996 Feb 15; 39(4):249-54. PubMed ID: 8645771
    [Abstract] [Full Text] [Related]

  • 11. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
    Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W.
    J Clin Psychopharmacol; 1993 Feb 15; 13(1):25-40. PubMed ID: 7683702
    [Abstract] [Full Text] [Related]

  • 12. Clozapine for refractory schizophrenia: an open study of 14 patients treated up to 2 years.
    Mattes JA.
    J Clin Psychiatry; 1989 Oct 15; 50(10):389-91. PubMed ID: 2571612
    [Abstract] [Full Text] [Related]

  • 13. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D, Thomas P, Leroux JM, Vaiga G, Pommery J, Cottencin O, Erb F, Goudemand M.
    Encephale; 1995 Oct 15; 21(6):417-24. PubMed ID: 8674466
    [Abstract] [Full Text] [Related]

  • 14. Antipsychotic medication in the treatment of schizophrenia.
    Kane JM.
    Isr J Psychiatry Relat Sci; 1995 Oct 15; 32(1):30-7. PubMed ID: 7542642
    [Abstract] [Full Text] [Related]

  • 15. [Patient modified medication: how do schizophrenic patients manage their neuroleptics?].
    Hornung WP, Buchkremer G, Redbrake M, Klingberg S.
    Nervenarzt; 1993 Jul 15; 64(7):434-9. PubMed ID: 8103569
    [Abstract] [Full Text] [Related]

  • 16. Does the cholecystokinin antagonist proglumide possess antipsychotic activity?
    Innis RB, Bunney BS, Charney DS, Price LH, Glazer WM, Sternberg DE, Rubin AL, Heninger GR.
    Psychiatry Res; 1986 May 15; 18(1):1-7. PubMed ID: 3737785
    [Abstract] [Full Text] [Related]

  • 17. [Drug management and therapy resistance. A cross-sectional study of schizophrenic patients in a large psychiatric hospital].
    Mohr F, Bender W, Hubmann W, Mäsel K, Pior R.
    Psychiatr Prax; 1992 Jul 15; 19(4):108-13. PubMed ID: 1354878
    [Abstract] [Full Text] [Related]

  • 18. [The use of the bromocriptine test in schizophrenia patients resistant to neuroleptic therapy].
    Ryzhakov BA, Nuller IU.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1992 Jul 15; 92(3):79-80. PubMed ID: 1359722
    [Abstract] [Full Text] [Related]

  • 19. A clinical trial of the effects of estrogen in acutely psychotic women.
    Kulkarni J, de Castella A, Smith D, Taffe J, Keks N, Copolov D.
    Schizophr Res; 1996 Jul 05; 20(3):247-52. PubMed ID: 8827850
    [Abstract] [Full Text] [Related]

  • 20. Adjunctive fluoxetine improves global function in chronic schizophrenia.
    Goldman MB, Janecek HM.
    J Neuropsychiatry Clin Neurosci; 1990 Jul 05; 2(4):429-31. PubMed ID: 1983785
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.